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Background
Upper gastrointestinal (UGI) haemorrhage is a major cause of morbidity, mortality and medical care costs, with peptic ulcer (PU) being the most frequent source of bleeding.
It has been estimated that approximately 2-3% of duodenal ulcer (DU) patients who are not receiving antisecretory therapy are likely to develop haemorrhage during each year of followup, giving a cumulative risk of haemorrhage after 5 years of approximately 10-14%. Furthermore, patients whose ulcers have bled once have an increased risk of further bleeding, compared with those with uncomplicated ulcer disease. Thus, among patients who present with a bleeding ulcer, approximately one-third will develop recurrent bleeding in the following 1-2 years, and 40-50% within the subsequent 10 years, if left untreated after initial healing.
Objectives
The objectives were as follows:
• to evaluate the clinical effectiveness and costeffectiveness of proton pump inhibitors (PPIs) in the prevention and treatment of acute UGI haemorrhage • to evaluate the clinical effectiveness and costeffectiveness of PPI therapy, compared with H 2 -receptor antagonist (H 2 RA), Helicobacter pylori eradication (in infected patients) or no therapy, for the prevention of first and/or subsequent bleeds among patients who continue to use nonsteroidal anti-inflammatory drugs (NSAIDs) • to evaluate the clinical effectiveness of PPI therapy, compared with H 2 RA, H. pylori eradication (in infected patients) or no therapy, for the prevention of subsequent bleeds in patients who had previously experienced peptic ulcer bleeding.
Methods
For the first objective, evidence was sought with the Cochrane Collaboration methodology from two systematic literature reviews of randomised Data from these systematic reviews and other sources were then entered into a Markov model with a Monte Carlo simulation to identify the most cost-effective treatment strategy for the prevention of UGI bleeding (first and subsequent) among NSAID users using an outcome of costs per quality-adjusted life-years (QALYs) over a lifetime from age 50 years. PPI treatment initiated prior to endoscopy in UGI bleeding significantly reduced the proportion of patients with stigmata of recent haemorrhage (SRH) at index endoscopy compared with placebo or H 2 RA (OR 0.67, 95% CI 0.54 to 0.84; NNT 11, 95% CI 7 to 25). However, there was no evidence that PPI treatment affected clinically important outcomes, namely mortality, re-bleeding or need for surgery.
The strategy of giving oral PPI both before and after endoscopy, with endoscopic haemostatic therapy (EHT) for those with major SRH, is likely to be the most cost-effective. Under base-case assumptions, this strategy is preferred to all other modelled strategies on cost-effectiveness grounds at any threshold over £25,000 per QALY, even if only short-term effects are taken into account, and at any threshold over £200 per life-year gained if long-term effects are included. H. pylori eradication treatment was equally effective with PPI treatment for the primary or secondary prevention of endoscopic ulcers in NSAID users. H. pylori eradication treatment was more effective than placebo for the primary prevention of endoscopic PU and for the prevention of rebleeding from PU in NSAID users.
With regard to primary and secondary prevention of bleeding PU in NSAID users, the two most costeffective strategies are H. pylori eradication alone, and H. pylori eradication followed by misoprostol (substituted for a PPI, if misoprostol is not tolerated) at an additional £4810 per QALY. In a Monte Carlo analysis, H. pylori eradication strategy appears to be cost-effective compared with doing nothing for almost all patients at any level above £80/QALY. The H. pylori eradication followed by misoprostol strategy is 90% likely to be cost-effective compared with doing nothing for a willingness to pay of £500/QALY, rising to 99% at £1000/QALY. Under most reasonable assumptions, strategies involving PPI use (either alone or in combination with H. pylori eradication) are not cost-effective.
In patients who had previously experienced a bleed from a PU, re-bleeding was less frequent after H. pylori eradication therapy than after non-eradication antisecretory therapy, whether or not the latter was combined with long-term maintenance antisecretory therapy (OR 0.17, 95% CI 0.10 to 0.32 and OR 0.25, 95% CI 0.08 to 0.76, respectively). The NNT to prevent one 
Conclusions
PPI treatment compared with placebo or H 2 RA reduces mortality following PU bleeding among patients with high-risk endoscopic findings. It also consistently reduces rates of re-bleeding and the need for surgical intervention. PPI treatment initiated prior to endoscopy in UGI bleeding significantly reduces the proportion of patients with SRH at index endoscopy but does not reduce mortality, re-bleeding or the need for surgery. The strategy of giving oral PPI before and after endoscopy, with EHT for those with major SRH, is likely to be the most cost-effective.
Treatment of H. pylori infection is more effective than antisecretory therapy (with or without longterm maintenance antisecretory therapy) in preventing recurrent bleeding from PU. H. pylori eradication alone or H. pylori eradication followed by misoprostol (with switch to PPI, if misoprostol is not tolerated) are the two most cost-effective strategies for preventing bleeding ulcers among H. pylori-infected NSAID users, although the data cannot exclude PPIs also being cost-effective.
Implications for healthcare
No specific recommendation either for or against PPI use before endoscopy can be made. PPI treatment should be administered to patients with endoscopically documented PU bleeding.
Based solely on the results of our meta-analysis, no specific conclusions can be drawn with regard to PPI dose or mode of administration. Nevertheless, if an oral PPI is used, the dose should be at least twice the standard clinical dose for that PPI. Based on the results of our economic modelling, the strategy of administering oral PPI both before and after endoscopy, with EHT for those with active bleeding or a non-bleeding visible vessel, is likely to be the most cost-effective.
It is suggested that H. pylori-infected NSAID users should receive appropriate eradication treatment, followed by misoprostol, at least 200 g twice daily. If misoprostol is not tolerated, it should be substituted for standard clinical dose PPI. The above strategy is likely to be the most cost-effective.
Recommendations for further research
PPIs in the acute hospital management of patients with UGI bleeding
• The issue of PPI administration prior to endoscopic diagnosis needs to be explored further in large RCTs in which patients with acute UGI bleeding are randomised to PPI therapy before endoscopy.
• A large, multicentre trial is needed in Europe and North America that would randomise patients to high-dose intravenous PPI or control treatment after any appropriate endoscopic intervention and address mortality as the primary end-point. Unfortunately, there are major obstacles to such a trial.
• Randomised trials directly comparing different doses of PPIs and/or oral and intravenous administration of PPIs in patients with PU bleeding are also needed.
• There is very limited evidence on head-to-head clinical outcome comparisons between different PPIs in PU bleeding, so such trials may be relevant.
PPIs in the primary and secondary prevention of UGI bleeding
• Large-scale randomised trials in patients commencing long-term NSAID therapy of the effect of PPIs, misoprostol and H. pylori eradication on the primary prevention of actual UGI bleeds are urgently required. The efficacy of combination therapy with PPI plus low-dose misoprostol could also be studied.
• Similar randomised trials in secondary prevention among NSAID users who have had a UGI bleed are also required, but these should include the option of stopping NSAIDs altogether. T he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA Programme then commissions the research by competitive tender. Secondly, the HTA Programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour. Thirdly, through its Technology Assessment Report (TAR) call-off contract, the HTA Programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies. Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem. The final reports from HTA projects are peer-reviewed by a number of independent expert referees before publication in the widely read monograph series Health Technology Assessment.
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